Results 251 to 260 of about 353,107 (313)

CCT2 Promotes Prostate Cancer Progression Through EIF3F‐Dependent Stabilization of FASN

open access: yesAdvanced Science, EarlyView.
ABSTRACT Prostate cancer (PCa) is increasingly recognized to be driven by dysregulated lipid metabolism. Although fatty acid synthase (FASN) is highly expressed in PCa, the mechanisms governing FASN protein stability and its functional integration into oncogenic lipid metabolism remain poorly defined.
Shun Xu   +13 more
wiley   +1 more source

Specificity and recognition of the ADP-ribosyl-ubiquitin modification in the DNA damage response. [PDF]

open access: yesPLoS Biol
Chatrin C   +14 more
europepmc   +1 more source

PDIA6–SCD1 Axis Rewires Lipid Metabolism to Drive Gastric Cancer Progression

open access: yesAdvanced Science, EarlyView.
Protein disulfide isomerase A6 (PDIA6) is identified as an oncogenic driver in gastric cancer. PDIA6 directly binds and stabilizes SCD1 by limiting its ubiquitin–proteasome‐mediated degradation, thereby sustaining monounsaturated fatty acid (MUFA)‐enriched lipid homeostasis and lipid metabolic reprogramming.
Zhen Tian   +13 more
wiley   +1 more source

RNF138‐Mediated Ubiquitination and Degradation of NS5 Restricts Tick‐Borne Encephalitis Virus Infection

open access: yesAdvanced Science, EarlyView.
Host‐specific compatibility between RNF138‐like proteins and flavivirus NS5 determines NS5 stability. Mammalian RNF138 but not arthropod homologs recognizes and induces conserved NS5/RdRp K48‐linked ubiquitination and proteasomal degradation, thereby restricting viral replication. Ectopic RNF138 in mice attenuates TBEV‐induced pathogenesis. (Created in
Jialiang Sun   +6 more
wiley   +1 more source

Ubiquitin-conjugating enzyme membrane anchor Cue1 confers resistance to hygromycin B in <i>Saccharomyces cerevisiae</i>. [PDF]

open access: yesMicroPubl Biol
Avaala JA   +7 more
europepmc   +1 more source

Allosteric Inhibition of Polycomb Repressive Complex 2 by an EZH2‐Selective Small Molecule Inhibitor

open access: yesAdvanced Science, EarlyView.
The study characterizes C36, a highly selective EZH2/PRC2 inhibitor that acts via a novel allosteric mechanism. Unlike previous inhibitors, C36 inhibits EZH2/PRC2 by disrupting the allosteric communication between EZH2 and EED in a SAM‐noncompetitive manner.
Ting Cao   +11 more
wiley   +1 more source

Home - About - Disclaimer - Privacy